И его применение при заболеваниях легких
жүктеу/скачать 142,06 Kb. Pdf көрінісі
|
1089-757-1-PB
Өкпенің ауамен
| Oyarzun M. J., Stevens P., Clemens J. A.
Effect of lung collapse on alveo lar surfactant in rabbits subjected to unilateral pneumothorax. Exp. Lung Res. 1989; 15: 90—96. 18. Hallman M., Maasita P., Kivisaari L. et al. Changes in surfactant in bron choalveolar lavage fluid after hemithorax irradiation in patients with mesothelioma. Am. Rev. Respir. Dis. 1990; 141: 998—1007. 19. Ackerman S. J., Kwatia M. A., Doyle C. B. et al. Hydrolysis of surfactant phospholipids catalyzed by phospholipase A2 and eosinophil lysophos pholipases causes surfactant dysfunction: a mechanism for small airway closure in asthma. Chest 2003; 123: 355—361. 20. Cheng G., Ueda T., Numao T. et al. Increased levels of surfactant protein A and D in bronchoalveolar lavage fluids in patients with bronchial asthma. Eur. Respir. J. 2000; 16: 831—835. 21. Haczku A., Atochina E. N., Tomer Y. et al. The late asthmatic response is linked with increased surface tension and reduced surfactant protein B in mice. Am. J. Physiol. Lung Cell Mol. Physiol. 2002; 283: 755—760. 22. Hohlfeld J., Ahlf K., EnhorningG. et al. Dysfunction of pulmonary sur factant in asthmatics after segmental allergen challenge. Am. J. Respir. Crit. Care Med. 1999; 159: 1803—1809. 23. Hohlfeld J. M., Schmiedl F., Erpenbeck V. J. et al. Eosiniphil cationic pro tein (ECP) alters pulmonary structure and function in asthma. J. Allergy Clin. Immunol. 2004; 113: 496—502. 24. Wang J. Y., Shieh C. C., Yu C. K. et al. Allergeninduced bronchial inflam mation is associated with decreased levels of surfactant proteins A and D in a murine model of asthma. Clin. Exp. Allergy 2001; 31: 652—662. 25. Wright S. M., Hockey P. M., Enborning G. et al. Altered airway surfactant phospholipids composition and reduced lung function in asthma. J. Appl. Physiol. 2000; 89: 1283—1292. 26. Devendra G. Spragg R. G. Lung surfactant in subacute pulmonary dis ease. Respiratory Res. 2002; 3: 19—30. 27. G ü nther A. et al. Surfactant abnormalities in idiopathic pulmonary fibrosis, hypersensitivity pneumonitis and sarcoidosis. Eur. Respir. J. 1999; 14: 565—576. 28. Ерохин В. В. Морфофункциональное состояние клеток легких при туберкулезном воспалении. В кн.: Ерохин В. В., Романова Л. К. (ред.) Клеточная биология легких в норме и при патологии. Руко водство для врачей. М.: Медицина; 2000. 496—518. 29. Rosenberg O., Bautin A., Osovskich V. et al. Surfactant therapy for acute and chronic lung diseases. Appl. Cardiopulm. Pathophysiol. 2004; 13 (1): 78—78. 30. Fujiwara T., Maeta H., Chida S. et al. Artificial surfactant therapy in hyaline membrane disease. Lancet 1980; 1: 55—59. 31. Lachmann B. Surfactant replacement in acute respiratory failure: Animal studies and first clinical trials. In.: Lachmann B. (ed.) Surfactant replacement тherapy. N. Y.: SpringerVerlag; 1987. 212—220. 32. Spragg R. G. Current status of surfactant treatment of ARDS/ALI. Appl. Cardiopulm. Pathophysiol. 2004; 13 (1): 88—90. 33. Gregory T. J., Gadek J. E., Weiland J. E. et al. Survanta supplementation in patients with acute respiratory distress syndrome (ARDS). Am. J. Resp. Crit. Care Med. 1994; 49: 125—131. 34. Rosenberg O. A., Bautin A. E., Osovskich V. V. et al. When to start sur factant therapy (STtherapy) of acute lung injury? Eur. Respir. J. 2001; 18 (Suppl. 38): 153, 7s. 35. жүктеу/скачать 142,06 Kb. Достарыңызбен бөлісу:
|